ProKidney (NASDAQ:PROK) and ReNeuron Group (OTCMKTS:RNUGF) Critical Comparison

ReNeuron Group (OTCMKTS:RNUGF) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ReNeuron Group and ProKidney, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
ProKidney	1	1	3	0	2.40

ProKidney has a consensus price target of $6.25, indicating a potential upside of 152.02%. Given ProKidney’s stronger consensus rating and higher probable upside, analysts plainly believe ProKidney is more favorable than ReNeuron Group.

Institutional and Insider Ownership

51.6% of ProKidney shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

ReNeuron Group has a beta of -0.57, suggesting that its stock price is 157% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.

Profitability

This table compares ReNeuron Group and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
ProKidney	N/A	N/A	-17.11%

Valuation and Earnings

This table compares ReNeuron Group and ProKidney”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	$640,000.00	N/A	-$6.52 million	N/A	N/A
ProKidney	$527,000.00	1,384.86	-$61.19 million	($0.57)	-4.35

ReNeuron Group has higher revenue and earnings than ProKidney.

Summary

ProKidney beats ReNeuron Group on 6 of the 9 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.